Mutations in the BRAF and N-ras genes in childhood acute lymphoblastic leukaemia Leukemia (2005) Although cure rates in childhood acute lymphoblastic leukaemia (ALL) have improved with a current long-term event-free 5-year survival of 80%, the role of molecular aberrations on the prognosis of leukaemia remains to be understood. Cytogenetic abnormalities in leukaemic cells can be detected in 90% of all cases, and aberrations such as hyperploidy and 2 The Ras/Raf/mitogen-activated protein kinase cascade couples signals from cell surface receptors to transcription factors that regulate gene expression. Depending upon the stimulus and cell type, this pathway can transmit signals, resulting in the prevention or induction of apoptosis or cell cycle progression. N-ras or K-ras mutations, which lead to constitutive activation of Raf/Mek/Erk pathway, occur in a proportion of acute myeloid leukaemia (AML) and ALL. 3 Mutations in BRAF, which is one of the downstream intermediates in the Ras/Raf/MAP kinase pathway, have been reported with a high frequency in melanomas. 4 Recently, BRAF mutations have also been identified in colorectal cancers, ovarian tumours, lung cancer and thyroid cancer. The BRAF gene is not a common target in AML patients and in patients with plasma cell leukaemia or multiple myeloma. 5, 6 In a recent report on acute leukaemia, a low frequency of mutations was reported in the G-loop within the kinase domain of BRAF. 7 Considering the importance of the Ras/Raf/MAP-kinase pathways in leukaemia, we examined bone marrows from 29 cases of childhood ALL for mutations in the N-ras and BRAF genes.
Paraffin-embedded bone marrow specimens from 29 childhood acute leukaemia patients were taken from Karolinska University Hospital archives. The age of leukaemia patients ranged between 1 and 19 years and a complete follow-up was maintained. Bone marrow samples from the time of diagnosis of ALL were obtained from 13 children who remained in a relapsefree survival (with complete remission from the original leukaemia) for more than 5 years after diagnosis (Table 1 ). In total, 16 bone marrow samples from the time of primary diagnosis of more aggressive ALL were also available. All these 16 patients went through bone marrow transplantation (BMT) because of relapse or known bad prognostic factors at the time of diagnosis (Table 1) .
DNA was extracted from paraffin-embedded tissues after deparaffinization using proteinase K digestion method. Exons 11 and 15 of the BRAF gene and exons 1 and 2 of the N-ras gene were amplified for SSCP analysis using primers described earlier. 8 PCR was carried out in a 10-ml volume reaction containing 50 mM KCl, 0.11 mM each dNTP, 1 mCi[a-32 P]dCTP, 0.3 U Taq DNA polymerase, 1-2 mM MgCl 2 and 0.15-0.3 mM of each primer. PCR amplified products were electrophoresed on a 0.5 Â MDE gel in at least three different conditions. Mutations Table 1 Risk group data at diagnosis and clinical outcome of 29 children with acute lymphoblastic leukaemis (ALL) analysed for mutations in the BRAF and N-ras genes The time from diagnosis to relapse in months. Correspondence detected by SSCP in different exons of the BRAF and N-ras genes were identified and confirmed by direct sequencing using Rhodamine dye terminator cycle sequencing kit (Big Dye; Applied Biosystems) as described earlier. 8 The sequencing data were analysed using Align software in DNA star software package. The study protocol was approved by medical ethics committee of the Karolinska Institute at Karolinska University Hospital, Stockholm, Sweden.
Out of total 29 bone marrow samples analysed from childhood ALL, mutations in the BRAF and N-ras genes were detected in 12 cases, six in the BRAF and seven in N-ras; one patient harboured mutations in the both genes ( Table 1 ). All the mutations in the BRAF gene were present in exon 15 and none in exon 11 ( Table 1 ). The T1799A (V600E; previously V599E 8 ) mutation, the most common change in the BRAF gene in melanoma and other cancers, was detected only in one case (case 15). Interestingly, three tumours (cases 2, 5 and 24) carried a T1790A mutation in codon 597 (CTA4CAA), resulting in amino-acid change from leucine to glutamine. In one tumour sample, a G1786A mutation resulted in glycine to serine change in codon 596 (case 25). In addition, G1768A mutation (case 10) at codon 590 caused valine to isoleucine amino-acid change. This leukaemia also simultaneously carried mutation in codon 61 of the N-ras gene. In five cases mutations in the N-ras gene involved codon 61, whereas in two cases the mutation was present in codon 13 ( Table 1 ). The mutations in the BRAF/N-ras gene did not show any statistical correlation with any of the clinical parameters. As can be observed, our data showed that frequency of the N-ras mutations in the acute leukaemia in this study is higher than that reported previously. 3 Interestingly, the mutational pattern in the BRAF gene detected in acute leukaemia in this study was distinct from that reported for other cancers. By far, the highest frequency of mutations in the BRAF gene has been reported in melanoma and the pre-dominant mutation affects a single valine residue at codon 600, which is substituted either with a basic or acidic residue. In the present study, we detected V600E mutation in only one patient. However, in other patients, the mutations were spread over the kinase activation domain, with three patients carrying a mutation at codon 597 where leucine was substituted with glutamine. The L597V mutant found in cholangiocarcinoma and lung carcinoma results in intermediate increase in kinase activity compared to wild-type BRAF as shown in in vitro studies. 9 The functional significance of most of the mutations found in this study is unknown, though all mutations are located within the kinase activation domain of BRAF. In a recent study on characterization of catalytic activity of various BRAF mutations, it has emerged that some of the mutations detected in tumours so far have even lower kinase activity than wild-type protein and surprisingly such mutants stimulate MEK by activating endogenous C-RAF. Thus, it is possible that BRAF in human cancers types is affected by more diverse and distinct mutations compared to other oncogenes. 9 In this study, with a single exception, mutations in BRAF and N-ras were mutually exclusive as has been observed in other tumours. In one case where the overlapping mutations were present, functional relevance of BRAF mutation is not known and additionally the presence of polyclonal cell population in a tumour is a possibility.
We did not observe any association between mutations in BRAF and N-ras genes and disease relapse or disease-free survival or any other clinical parameter. Though at present we lack any evidence, it is possible that these mutations in a subset of childhood acute leukaemia represent an early event. As mutated BRAF proteins have elevated kinase activity, the screening may provide new therapeutic opportunities on the lines similar to Bcr-Abl positive leukaemia where treatment with a selective tyrosine kinase inhibitor elicits positive response. 10 
